A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

NCT06719362 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: M3T01
DRUG: Pembrolizumab
RADIATION: Chemoradiation
DRUG: FOLFOX regimen

Sponsor

Providence Health & Services